Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer

British Journal of Cancer

Volumn 92, Issue 6, 2005, Pages 1013-1018

  Yeh, K H ^a,b,c   Lu, Y S ^a,b   Hsu, C H ^a,b   Lin, J F ^b   Chao, H J ^b   Huang, T C ^b   Chung, C Y ^d   Chang, C S ^d   Yang, C H ^a,b   Cheng, A L ^a,b,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Breast cancer; High dose 5 FU and leucovorin; Weekly vinorelbine

Indexed keywords

FLUOROURACIL; FOLINIC ACID; NAVELBINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VINBLASTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BRAIN DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; HYPERAMMONEMIA; INFECTION; LEUKOPENIA; LIVER TOXICITY; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; BREAST TUMOR; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; PROSPECTIVE STUDIES; VINBLASTINE;

EID: 20244374714     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602469     Document Type: Article

References (48)

1. Abeloff MD (1995) Vinorelbine (Navelbine) in the treatment of breast cancer: a summary. Semin Oncol 22(2 Suppl 5): 1-4
2. ACCMAP (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10: 896-903
3. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L (1991) A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625-630
4. Baldini E, Tibaldi C, Chiavacci F, Di Lieto M, Fioretto L, Giallom-bardo A, Taviani R, Ghezzi P, Bolognini A, Conte P (1998) Epirubicin/vinorelbine as first line therapy in metastatic breast cancer. Breast Cancer Res Treat 49: 129-134
5. Bertino JR (1997) Biomodulation of 5-fluorouracil with antifolates. Semin Oncol 24(5 Suppl 18): 52-56
6. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20: 3114-3121
7. Bruno S, Puerto VL, Mickiewicz E, Hegg R, Texeira LC, Gaitan L, Martinez L, Fernandez O, Otero J, Kesselring G (1995) Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 18: 392-396
8. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN (2002) Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 8: 1073-1079
9. Canobbio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, Santi L (1989) Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 16(2 Suppl 4): 33-36
10. Clavel M, Catimel G (1993) Breast cancer: chemotherapy in the treatment of advanced disease. Eur J Cancer 29A: 598-604
11. Davidson NE (2002) Ongoing US cooperative group trials using taxanes in the adjuvant setting. Clin Breast Cancer 3(Suppl 2): S53-S58
12. Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P, Marty M (1996a) Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14: 3097-3104
13. EBCTCG (1992a) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339: 71-85
14. EBCTCG (1992b) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339: 1-15
15. EBCTCG (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942
16. Fine S, Erlichman C, Kaizer L, Warr D, Gadalla T (1994) Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer. Breast Cancer Res Treat 30: 205-209
17. Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C (2001) Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 7: 3934-3941
18. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM (1997) Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 35: 47-53
19. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245-1252
20. Fumoleau P, Delozier T, Extra JM, Canobbio L, Delgado FM, Hurteloup P (1995) Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience. Semin Oncol 22(2 Suppl 5): 22-28
21. Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, De Pablo JL, Gorostiaga J, Giron GC, Cervantes A (1994) Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5: 854-857
22. Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J (1999) Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17: 3038-3047
23. Grem JL (2001) Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer. Oncology 15(1 Suppl 2): 13-19
24. Grem JL, Hoth DF, Hamilton JM, King SA, Leyland-Jones B (1987) Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 71: 1249-1264
25. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983
26. Hortobagyi GN (1995) Future directions for vinorelbine (Navelbine). Semin Oncol 22(2 Suppl 5): 80-86
27. Horton J (1996) 1995 Oxford breast cancer overview - preliminary outcomes. Cancer Control 3: 78-79
28. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, Cheng AL (1997) Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition. Oncology 54: 275-280
29. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707-1715
30. Klaassen U, Wilke H, Pari CP, Strumberg D, Harstrick A, Eberhardt W, Becher R, Diergarten K, Seeber S (1995) Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis. Semin Oncol 22(6 Suppl 14): 7-11
31. Klaassen U, Wilke H, Seeber S (1996) Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. Semin Oncol 23(5 Suppl 11): 32-37
32. Kornek GV, Haider K, Kwasny W, Lang F, Krauss G, Hejna M, Raderer M, Weinlander G, Depisch D, Scheithauer W (1998) Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and 1-leucovorin plus human granulocyte colony-stimulating factor. Br J Cancer 78: 673-678
33. Krikorian A, Breillout F (1991) Vinorelbine (Navelbine). A new semisynthetic vinca alkaloid. Onkologie 14: 7-12
34. Lombardi D, Magri MD, Crivellari D, Spazzapan S, Paolello C, De Cicco M, Di Lauro V, Scuderi C, Veronesi A (2000) Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. Ann Oncol 11: 1041-1043
35. Mathe G, Reizenstein P (1985) Phase I pharmacologic study of a new Vinca alkaloid: navelbine. Cancer Lett 27: 285-293
36. Nole F, de Braud F, Aapro M, Minchella I, De Pas M, Zampino MG, Monti S, Andreoni G, Goldhirsch A (1997) Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 8: 865-870
37. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A (2000) Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18: 2385-2894
38. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ (1995) Paclitaxel-induced neuropathy. Ann Oncol 6: 489-494
39. Razis ED, Fountzilas G (2001) Paclitaxel: epirubicin in metastatic breast cancer - a review. Ann Oncol 12: 593-598
40. Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, Blumenschein GR, Freireich EJ, Gehan EA (1985) Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 55: 341-346
41. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592
42. Smith GA (1995) Current status of vinorelbine for breast cancer. Oncology (Huntingt) 9: 767-773
43. Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T (1994) Phase II trial of vinorelbine/ doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12: 1764-1770
44. Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75: 464-465
45. Yeh KH, Cheng AL (1998) Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin. Br J Haematol 100: 769-772
46. Yeh KH, Cheng AL, Lin MT, Hong RL, Hsu CH, Lin JF, Chang KJ, Lee PH, Chen YC (1997) A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers. Anticancer Res 17: 3867-3871
47. Yeh KH, Yeh SH, Chang YS, Cheng AL (2000a) Minimal toxicity to myeloid progenitor cells of weekly 24-hr infusion of high-dose 5-fluorouracil: direct evidence from colony forming unit-granulocyte and monocyte (CFU-GM) clonogenic assay. Pharmacol Toxicol 86: 122-124
48. Yeh KH, Yeh SH, Hsu CH, Wang TM, Ma IF, Cheng AL (2000b) Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil. Br J Cancer 83: 1510-1515